GREENFIRE BIO
Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early-stage assets through proof of concept and investing in unique medical breakthroughs. Greenfire typically licenses, acquires, partners, or invests in differentiated pre-clinical or early clinical-stage programs to bridge the translational medicine gap and accelerate development.
GREENFIRE BIO
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Ajit Gill President & CEO @ Greenfire Bio
President & CEO
2020-07-01
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-02 | Pacylex | Greenfire Bio investment in Series A - Pacylex | N/A |
More informations about "Greenfire Bio"
Home - Greenfire Bio
Greenfire Bio (GFB) GFB is an oncology focused clinical stage biopharma company that looks to collaborate with, in-license or acquire early-stage assets and develop them through clinical …See details»
Greenfire Bio - Crunchbase Investor Profile & Investments
Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early …See details»
Greenfire Bio - LinkedIn
Greenfire Bio is a diversified life science company led by a team of experienced business and development executives building a product portfolio by addressing the chronic mismatch …See details»
Pacylex Pharmaceuticals Closes Series A Funding to Advance …
Jun 4, 2021 Greenfire Bio Makes First External Investment Expanding Oncology Footprint. Edmonton, Alberta, Canada, and Austin Texas, US, June 2, 2021. Pacylex Pharmaceuticals, …See details»
Greenfire Bio Announces the acquisition of an IND-stage SIK2 …
Austin TX, December 16, 2020 — Greenfire Bio, LLC announced today that it has completed its first transaction, the acquisition of a first-in-class, orally bioavailable small molecule dual …See details»
Greenfire Bio investment portfolio - PitchBook
Greenfire Bio General Information Company Description. Greenfire Bio is a development and investment company. The company licenses, acquires, partners, or invests in differentiated pre-clinical or early clinical-stage …See details»
GRN-300 by Greenfire Bio for Triple-Negative Breast Cancer (TNBC ...
Dec 30, 2024 Greenfire Bio overview. Greenfire Bio (Greenfire) is a clinical-stage biopharmaceutical company developing drugs for treating cancer. Its products include GRN …See details»
Pacylex Pharmaceuticals Closes Series A Funding to Advance …
Jun 2, 2021 About Greenfire Bio Greenfire Bio, LLC is a development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by …See details»
Greenfire Bio - Facebook
Greenfire Bio. 7 likes. A diversified life science company led by a team of experienced biopharma executives building a broad product pipeline by developing early stage assets through proof of...See details»
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2 ...
FRISCO, Texas, May 31, 2022 /PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an …See details»
Major Grant Awarded to Study PCLX-001 in Acute Myeloid
Oct 11, 2022 US Department of Defense Awards $1.4 million for AML Study Edmonton, Alberta, Canada, October 11, 2022 Pacylex today announced that the US Department of Defense …See details»
Leadership team & SAB – Epok - EPOK Therapeutics
30+ years in the pharmaceutical and biotech industry. Held CBO, SVP of Business Development and Alliance Management, Executive Director Search & Evaluation, and Head of Structural …See details»
Pacylex - Funding, Financials, Valuation & Investors - Crunchbase
Organization. Pacylex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 5. obfuscated. ... U.S. …See details»
Greenfire Resources Announces New President and Departure of …
CALGARY, ALBERTA – February 11, 2025 – Greenfire Resources Ltd. (NYSE and TSX: GFR) (“Greenfire” or the “Company”) today announced the appointment of Colin Germaniuk, P.Eng., …See details»
Pacylex Pharmaceuticals Closes Series A Funding to Advance …
“The support from Greenfire Bio is essential for our transformation into a clinical stage company”, said Michael Weickert, CEO of Pacylex. “Pioneering a new target and first-in-class therapy is …See details»
M 002 - MGFB Bio - AdisInsight
M 002 is a recombinant cancer vaccine being developed by MGFB Bio which is a subsidiary of Greenfire Bio for the treatment of glioma. The vaccine is developed M 002 - MGFB Bio ... If …See details»
MGFB: Vaccinating Against Tumor Antigen Escape - Greenfire Bio
Dec 1, 2022 The Greenfire Bio subsidiary is developing xenogenic tumor antigen libraries delivered via engineered viruses. Article by Richard Guy, Biopharma Analyst MGFB is …See details»
Chris Searcy - Previous Director for Greenfire Bio Corp
Mar 2, 2024 Greenfire Bio Corp Inactive 2021 1 Director Advertisements. Source. Texas Secretary of State Data last refreshed on Saturday, March 2, 2024 What next? Follow. …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago Today, the Honourable Darren Fisher, Member of Parliament for Dartmouth – Cole Harbour, announced a $5 million, non-repayable contribution to Neptune BioInnovation Inc. to …See details»
Greenfire Bio
FRISCO, Texas, May 31, 2022 – PRNewswire Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an …See details»